A Selective Cyclooxygenase-2 Inhibitor, NS-398, Inhibits Cell Growth by Cell Cycle Arrest in a Human Malignant Fibrous Histiocytoma Cell Line

Anticancer Research

Volumn 23, Issue 6 C, 2003, Pages 4671-4676

  Yamashita, Hideki ^a   Osaki, Mitsuhiko ^a,c   Honjo, Soichiro ^a   Yoshida, Haruhiko ^b   Teshima, Ryota ^a   Ito, Hisao ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

Author keywords

COX 2; G0 G1 arrest; MFH; NS 398

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN MFH INO; CELL STRAIN MFH TOE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SELECTIVITY; ELECTROIMMUNOASSAY; GENE FUNCTION; HUMAN; HUMAN CELL; MALIGNANT FIBROUS HISTIOCYTOMA; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; SARCOMA CELL; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

CELL CYCLE; CELL DIVISION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTIOCYTOMA, BENIGN FIBROUS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; NITROBENZENES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 0842311694     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Fosslien E: Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 30: 3-21, 2000.
2. Needleman P, Turk J, Jakschik BA, Morrison AR and Lefkowith JB: Arachidonic acid metabolism. Annu Rev Biochem 55: 69-102, 1986.
3. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J and Isakson P: Distribution of COX-1 and COX-2 in normal and inflamed tissues. Adv Exp Med Biol 400A: 167-170, 1997.
4. Kujubu DA, Fletcher BS, Varnum BC, Lim RW and Herschman HR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 266: 12866-12872, 1991.
5. Smith WL, Garavito RM and DeWitt DL: Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2, J Biol Chem 271: 33157-33160, 1996.
6. Ristimaki A, Garfinkel S, Wessendorf J, Maciag T and Hla T: Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation. J Biol Chem 269: 11769-11775, 1994.
7. Hla T and Neilson K: Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 89: 7384-7388, 1992.
8. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M and DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716, 1998.
9. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM, Masferrer JL and Dannenberg AJ: Cyclooxygenase-2 expression is upregulated in squamous cell carcinoma of the head and neck. Cancer Res 59: 991-994, 1999.
10. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT and Masferrer JL: Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 62: 625-631, 2002.
11. Shiff SJ, Qiao L, Tsai LL and Rigas B: Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 96: 491-503, 1995.
12. Smith ML, Hawcroft G and Hull MA: The effect of nonsteroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur J Cancer 36: 664-674, 2000.
13. Hia T, Ristimaki A, Appleby S and Barriocanal JG: Cyclooxygenase gene expression in inflammation and angiogenesis. Ann NY Acad Sci 696: 197-204, 1993.
14. Gupta RA and DuBois RN: Aspirin NSAIDS and colon cancer prevention: mechanism? Gastroenterology 114: 1095-1098, 1998.
15. Liu XH, Yao S, Kirschenbaum A and Levine AC: NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 58: 4245-4249, 1998.
16. Lee DW, Sung MW, Park SW, Seong WJ, Roh JL, Park B, Heo DS and Kim KH: Increased cyclooxygenase-2 expression in human squamous cell carcinomas of the head and neck and inhibition of proliferation by nonsteroidal anti-inflammatory drugs. Anticancer Res 22: 2089-2096, 2002.
17. Weiss SW and Goldblum JR(eds): Malignant fibrohistiocytic tumors. In: Enzinger and Weiss's Soft Tissue Tumors. Fourth edition. St. Louis, CV Mosby, pp535-569, 2002.
18. Moalic S, Liagre B and Le Bail JC: Dose-dependent modulation of apoptosis and cyclooxygenase-2 expression in human 1547 osteosarcoma cells by NS-398, a selective cyclooxygenase-2 inhibitor. Int J Oncol 18: 533-540, 2001.
19. Raju U, Nakata E, Yang P, Newman RA, Ang KK and Milas L: In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations. Int J Radiat Oncol Biol Phys 54: 886-894, 2002.
20. Endo K, Sakatani T, Watanabe M, Yoshida H, Nanba E and Ito H: Wild-type p53 gene transfer resulted in cell cycle arrest, but not apoptosis of newly established human malignant fibrous histiocytoma cell line. Int J Oncol 15: 935-942, 1999.
21. Labaer J, Garrett MD, Stevenson LF, Slingerland JM, Sanduh C, Chou HS, Fattaey A and Harlow E: New functional activities for the p21 family of CDK inhibitors. Genes Dev 11: 847-862, 1997.
22. Toyoshima T, Kamijo R, Takizawa K, Sumitani K, Ito D and Nagumo M: Inhibitor of cyclooxygenase-2 induces cell cycle arrest in the epithelial cancer cell line via up-regulation of cyclin dependent kinase inhibitor p21. Br J Cancer 86: 1150-1156, 2002.
23. Williams CS, Smalley W and DuBois RN: Aspirin use and potential mechanism for colorectal cancer prevention. J Clin Invest 100: 1325-1329, 1997.
24. Cheng J, Imanishi H, Amuro Y and Hada T: NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines. Int J Cancer 99: 755-761, 2002.
25. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM, Masferrer JL and Dannenberg AJ: Cyclooxygenase-2 expression is upregulated in squamous cell carcinoma of the head and neck. Cancer Res 59: 991-994, 1999.
26. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H and Ristimaki A: Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58: 4997-5001, 1998.
27. DElder DJ, Halton DE, Hague A and Paraskeva C: Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res 3: 1679-1683, 1997.
28. Cheng J, Imanishi H, Amuro Y and Hada T: NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines. Int J Cancer 99: 755-761, 2002.
29. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML and Sinicrope FA: Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs Cancer Res 59: 4356-4362, 1999.
30. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y et al: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174, 1994.
31. Hunter T and Pines J: Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79: 573-582, 1994.
32. Sherr CJ and Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9: 1149-1163, 1995.
33. Osaki M, Osaki M, Yamashita H, Shomori K, Yoshida H and Ito H: Expression of minichromosome maintenance-2 in human malignant fibrous histiocytomas: Correlations with Ki-67 and P53 expression, and apoptosis. Int J Mol Med 10: 161-168, 2002.
34. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM and Chen CS: The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275: 11397-11403, 2000.
35. Trifan OC, Smith RM, Thompson BD and Hla T: Overexpression of cyclooxygenase-2 induces cell cycle arrest. Evidence for a prostaglandin-independent mechanism. J Biol Chem 274: 34141-34147, 1999.
36. Minter HA, Eveson JW, Huntley S, Elder DJ and Hague A: The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis. Clin Cancer Res 9: 1885-1897, 2003.
37. Hermann C, Block C, Geisen C, Haas K, Weber C, Winde G, Moroy T and Muller O: Sulindac sulfide inhibits Ras signaling. Oncogene 17: 1769-1776, 1998.
38. Waddell WR and Miesfeld RL: Adenomatous polyposis coli, protein kinases, protein tyrosine phosphatase: the effect of sulindac. J Surg Oncol 58: 252-256, 1995.
39. Yamamoto Y, Yin MJ, Lin KM and Gaynor RB: Sulindac inhibits activation of the NF-κB pathway. J Biol Chem 274: 27307-27314, 1999.
40. Chan TA, Morin PJ, Vogelstein B and Kinzler KW: Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95: 681-686, 1998.
41. Piazza TA, Rahm AK, Finn TS, Fryer BH, Li H, Stoumen AL, Pamukcu R and Ahnen DJ: Apoptosis primarily accounts for the growth inhibitory properties of sulindac metabolities and involves a mechanism that is independent of cyclooxygenase inhibition. Cell cycle arrest and p53 induction. Cancer Res 57: 2452-2459, 1997.
42. Yuzuru A, Shu O, S. Perwez H, Makoto N, Peijun H et al: Regulation of cyclooxygenase-2 by Wnt and Ras pathways. Cancer Res 63: 728-734, 2003.